Results 211 to 220 of about 2,000,070 (348)

Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies. [PDF]

open access: yesBlood Adv, 2023
Foley JH   +12 more
europepmc   +1 more source

Assessing the Sensitivity and the Clinical Impact of the 2023 American College of Rheumatology/EULAR Classification Criteria in Obstetric Antiphospholid Syndrome: Findings From a Multicenter Italian Cohort With a Long‐Term Follow‐Up

open access: yesArthritis Care &Research, EarlyView.
Objective The aim of this study was to evaluate the sensitivity of the 2023 American College of Rheumatology (ACR)/EULAR classification criteria for antiphospholipid syndrome (APS) in a real‐world cohort of women diagnosed with primary obstetric APS (oAPS) and to assess their ability to identify patients at risk of future pregnancy complications ...
Francesca Ruffilli   +10 more
wiley   +1 more source

A precision gene-engineered B cell medicine producing sustained levels of active factor IX for hemophilia B therapy. [PDF]

open access: yesMol Ther
Liu H   +25 more
europepmc   +1 more source

Factor IX San Dimas

open access: hybrid, 1989
Jerry Ware   +7 more
openalex   +1 more source

Effects of Causal Beliefs About Gout on Public Views About Gout Management: A Randomized Experimental Study

open access: yesArthritis Care &Research, EarlyView.
Objective Despite well‐described biologic causes, the public views unhealthy lifestyle choices as the primary cause of gout. This study investigated how causal beliefs about gout influence the public's views about its management. Methods In a randomized study, 201 members of the public viewed one of two 2‐minute videos about gout.
Rachel Murdoch   +6 more
wiley   +1 more source

Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy. [PDF]

open access: yesHaemophilia
Astermark J   +12 more
europepmc   +1 more source

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. [PDF]

open access: yesBlood Adv, 2023
Shapiro AD   +16 more
europepmc   +1 more source

Real‐world Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study

open access: yesArthritis Care &Research, Accepted Article.
Objectives Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus (SLE), yet the weight‐based dosing does not account for clinical factors that can introduce individual variability in drug metabolism and clearance. We leveraged longitudinal data from a prospective SLE cohort to: 1) identify clinical factors that predict ...
Jay J. Patel   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy